2 results
Approved WMOCompleted
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Approved WMOCompleted
To determine the difference in increase in cycle endurance time after PR using NHF oxygen supplementation in patients during both exercise training and night time compared to patients using a conventional oxygen delivery systems.